Navigation Links
ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics
Date:1/7/2011

terms and conditions that are materially different from the terms described in this press release; the risk that ADVENTRX may not be able to integrate the target company successfully into its operations or that it may incur unexpected costs and disruptions to its business as a result of such integration; the potential for the FDA to require ADVENTRX to perform additional nonclinical, or clinical studies prior to initiating or following completion of the currently contemplated phase 3 clinical trial of the TPC for the treatment of sickle cell crisis; the risk that subsequent nonclinical or clinical study results do not support the safety and efficacy or the commercial viability of the TPC or any other product candidate developed using technology acquired from the target company; the risk that the neither the FDA nor any other regulatory agency approves a product based on the TPC or any other product candidate developed using technology acquired from the target company on a timely basis, or at all; the potential for the out-of-pocket cost to ADVENTRX and the time required for development of the TPC necessary to support an NDA submission are greater than ADVENTRX's current expectations; the risk that the TPC loses its orphan drug designation for the treatment of sickle cell crisis or that a third party's product candidate is shown to be clinically superior and is approved by the FDA during the TPC's market exclusivity period; the risk that individuals previously involved in the development of the TPC will not assist ADVENTRX in further development of the TPC and that ADVENTRX may be unable to retain the services of other qualified individuals on a timely basis, or at all; ADVENTRX's planned reliance on third parties to assist with its nonclinical and clinical studies, regulatory submissions, manufacturing and other important aspects of the TPC development program, if it consummates a transaction with the target company, and the risk that FDA approval may be delayed if
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015   Mast ... biopharmaceutical company leveraging its molecular adhesion and sealant ... sickle cell disease, heart failure, and arterial disease, ... EPIC study of its lead product ... surpassed the halfway point. Consistent with prior guidance, ...
(Date:4/21/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5jt68c/global_api_market ) has ... 2018" report to their offering. Global API ... the Global API industry is expected to grow at a ... been divided into four major geographies which comprise Americas, ... the rest of the world. For every region, a current ...
(Date:4/21/2015)... MENLO PARK, Calif. , April 21, 2015 /PRNewswire/ ... company focused on the emerging field of regenerative medicine, ... patients with acute myelogenous leukemia (AML) from the Phase ... cell cancer vaccine, AST-VAC1, has been selected for an ... Oncology (ASCO) Annual Meeting, to be held in ...
Breaking Medicine Technology:Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 2Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 3Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 5Global API Market Outlook Report 2014-2018 2Global API Market Outlook Report 2014-2018 3Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 2Asterias Biotherapeutics Announces Phase 2 Clinical Data on Autologous Telomerase-based Dendritic Cell Cancer Vaccine AST-VAC1 Selected for Oral Presentation at the 2015 ASCO Annual Meeting 3
... , ... Albemarle Corporation (NYSE: ALB ), a leading global ... PharmaCore to provide manufacturing capabilities for customers with projects that require ... alliance allows a seamless technology transfer from PharmaCore to Albemarle ...
... , ... Systems, Inc. today announced full integration between AVImark veterinary software ... the two-way connection allows diagnostic test requisitions and patient data ... any AVImark workstation in a veterinary practice. Test results are ...
Cached Medicine Technology:Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 2Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 3Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 4Albemarle(R) Announces Custom Manufacturing Alliance with PharmaCore(R) 5McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010 2McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010 3McAllister Software Systems, Inc. and IDEXX Laboratories, Inc. Announce Availability of the IDEXX VetLab(R) Station InterLink(TM) Connection to AVImark(R) 2010 4
(Date:4/21/2015)... The American Society for Dermatologic Surgery is ... Brandt, M.D., by setting up two memorial funds in ... 1982, died earlier this month at age 65 at ... opportunities for ASDS members, industry and any interested donors ... Brandt held so dear. , “Dr. Brandt was one ...
(Date:4/21/2015)... 2015 NOVAtime Technology, Inc. ( ... and Attendance / Workforce Management solutions, announced its ... American Payroll Association (APA) as well as NetSuite’s ... has been the nation’s payroll authority since 1982, ... and recertification credits. Held at the MGA Grand ...
(Date:4/21/2015)... Saint Louis, MO (PRWEB) April 21, 2015 ... April 29, 2015 from 5:00 to 8:00 pm at the ... Center Drive, Chapel Hill, NC 27599. More than 50 hospitals, ... across the country. All specialties will be represented. Attendees will ... Thompson, Director of Career Fairs for PracticeMatch says ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Atlantic ... the launch of Medicare-Medicaid Dual Eligibles Database, a ... on care provided to the more than 9 ... account for more than $300 billion in annual ... – the same team that also creates the ...
(Date:4/21/2015)... eSight is the only technology in the world that helps ... May 5th, Low Vision Specialists of Maryland and Virginia ... unveiling and demonstration of the technology at 8:30 a.m at ... be the first ophthalmic practice in Maryland to offer the ... be available on the day of the unveiling. , How ...
Breaking Medicine News(10 mins):Health News:ASDS honors the legacy of Dr. Fredric Brandt 2Health News:ASDS honors the legacy of Dr. Fredric Brandt 3Health News:ASDS honors the legacy of Dr. Fredric Brandt 4Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 2Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 3Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:New AIS Database Tracks All Programs, Plans Serving the Dual-Eligible Community 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 2Health News:eSight Electronic Glasses That Enable The Legally Blind To See – First In The World – Coming To Maryland 3
... Study Reveals the Most Common Reasons Why Total Hip ... thousands of patients undergo total hip replacement surgery in ... disease and other related hip problems. According to ... of The Journal of Bone and Joint Surgery ...
... Jan. 2 Joan Lunden, the nation,s,longest-running morning ... two decades. During her tenure she reported ... two Royal weddings. One of the most,visible ... of her career to,educating Americans about health and ...
... ATLANTA, Jan. 2 Publix, Procter & Gamble, and,Special ... people with,intellectual disabilities achieve their dreams. Now they,re ... Special Olympics. , 1. Support ... by,purchasing your favorite P&G products like Tide, Pampers, Bounty ...
... tips on how to avoid injury while performing winter ... snow from your driveway and sidewalks can be physically ... proper health and safety precautions, says the American Academy ... than 118,000 people were treated in U.S. hospital emergency ...
... keep colds and flu at bay , , FRIDAY, Jan. 2 ... there,s one tidbit that doctors stand by as the best way ... free of germs is one of the simplest and most effective ... other infectious disease, experts say. , "Disease transmission is hand-to-hand combat, ...
... Va.In a study to determine the diagnostic value of ... cancer, researchers were able for the first time to ... and normal residual thyroid tissue directly after surgery. , ... an article in the January issue of The ...
Cached Medicine News:Health News:Replacing Your Total Hip Replacement 2Health News:Replacing Your Total Hip Replacement 3Health News:Joan Lunden Inks Three-Year Deal to Host Health Corner(R) Television Series 2Health News:'Be A Fan' of Special Olympics Throughout January 2Health News:Shovel Snow Safely 2Health News:To Protect Yourself, Wash Those Germs Away 2Health News:To Protect Yourself, Wash Those Germs Away 3Health News:To Protect Yourself, Wash Those Germs Away 4Health News:Molecular imaging enables earlier, individualized treatment of thyroid cancer 2
The DuraSeal System includes an innovative polyethylene glycol hydrogel sealant and applicator packaged in a single-use kit which can be stored at room temperature for convenience and quick preparati...
Mastisol Liquid Adhesive is a clear, non-irritating, and non-water-soluble liquid adhesive that secures the most difficult dressings for an extended period of time. Mastisol is 7 to 10 times stickier...
GluStitch® is indicated for the closure of uncomplicated skin lacerations where there is little or no tissue loss....
... GE Healthcare is ... in best-in-class analysis programs ... area monitoring device. With ... 12SL, Gender-Specific, and ACI-TIPI, ...
Medicine Products: